Agreement Assessment of Tigecycline Susceptibilities Determined by the Disk Diffusion and Broth Microdilution Methods among Commonly Encountered Resistant Bacterial Isolates: Results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) Study, 2008 to 2010

作者：Liu Jien Wei; Ko Wen Chien; Huang Cheng Hua; Liao Chun Hsing; Lu Chin Te; Chuang Yin Ching; Tsao Shih Ming; Chen Yao Shen; Liu Yung Ching; Chen Wei Yu; Jang Tsrang Neng; Lin Hsiu Chen; Chen Chih Ming; Shi Zhi Yuan; Pan Sung Ching; Yang Jia Ling; Kung Hsiang Chi; Liu Chun Eng; Cheng Yu Jen; Chen Yen Hsu; Lu Po Liang; Sun Wu; Wang Lih Shinn; Yu Kwok Woon; Chiang Ping Cherng; Lee Ming Hsun; Lee Chun Ming; Hsu Gwo Jong; Hsueh Po Ren^*

来源：Antimicrobial Agents and Chemotherapy, 2012, 56(3): 1414-1417.

DOI：10.1128/AAC.05879-11

The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is a nationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion-methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA; n = 759), vancomycin-resistant Enterococcus faecium (VRE; n = 191), extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (n = 602), ESBL-producing Klebsiella pneumoniae (n = 736), and Acinetobacter baumannii (n = 726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 mu g/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were %26lt;5% for MRSA, VRE, and ESBL-producing E. coli. For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods.

• 出版日期2012-3
• 单位长春大学; 河北医科大学